Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 716-731
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.716
Table 1 Baseline characteristics and comorbidities for herb nonusers and herb users in diabetes mellitus patients with regular insulin management in Taiwan between 2000 and 2017
VariablesDM patients with regular insulin use
SMD
Herb non-users, n = 140547
Herb users, n = 46849
n
%
n
%
Sex0.014
        Female7187251.142428851.84
        Male6867548.862256148.16
Age, yr
        20-40116238.2741608.880.022
        40-605523939.301868439.880.012
        > 607368552.432400551.240.024
Mean (SD)59.47 (13.25)59.11 (13.38)0.027
Comorbidities
        Hypertension10725576.313522375.180.026
        Coronary heart disease6001642.701986242.400.006
        Ischemic stroke3211722.851036622.130.017
        Hemorrhagic stroke34182.4311462.450.001
        Hyperlipidemia11402881.133770780.490.016
        Renal insufficiency2439417.36782316.700.018
        Cirrhosis49523.5218473.940.022
        Alcoholic liver damage103137.3433867.230.004
        Nonalcoholic fatty liver disease123988.8241788.920.003
        HBV infection95606.8034727.410.024
        HCV infection57704.1121074.500.019
Medication
Lipid-lowering drug
        Statin82175.8527665.900.003
        Non-statin139909.9542999.180.026
        Aspirin48903.4815593.330.008
        HBV treatment19471.396961.490.008
        HCV treatment4510.321920.410.015
OAD
        Biguanides91426.5030546.520.001
        Sulfonamide88556.3029146.220.003
        AGI2275916.19782916.710.014
        Thiazolidinediones2002214.25732515.640.039
        DPP4 inhibitors1431310.18564812.060.060
        GLP-1 receptor agonist29822.1213592.900.050
        SGLT2 inhibitors83765.9636397.770.072
        Glinide2529818.00888618.970.025
        Insulin dose (mg), mean (SD)9449.92 (135.59)8248.88 (115.34)0.071